Fecal-based DNA assays: A new, noninvasive approach to colorectal cancer screening

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 6, 2004, Pages 497-503

  Deenadayalu, Viju P ^a   Rex, Douglas K ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM; DNA;

BARIUM ENEMA; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CHROMOSOME DISORDER; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; DNA DETERMINATION; FECES ANALYSIS; GENE MUTATION; GENETIC STABILITY; HUMAN; NON INVASIVE MEASUREMENT; OCCULT BLOOD; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 3042547500     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.6.497     Document Type: Review

References (35)

1. Trends in screening for colorectal cancer - United States, 1997 and 1999. MMWR Morb Mortal Wkly Rep 2001; 50:162-166.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Smith RA, Von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 - testing for early lung cancer detection. CA Cancer J Clin 2001; 51:38-75.
4. U.S. Preventive Services Tasks Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002; 137:129-131.
5. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124:544-560.
6. Simmang CL, Senatore P, Lowry A, et al. Practice parameters for detection of colorectal neoplasms. The Standards Committee, The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1999; 42:1123-1129.
7. From the Centers for Disease Control and Prevention. Colorectal cancer test use among persons aged > or = 50 years - United States, 2001. JAMA 2003; 289:2492-2493.
8. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States. JAMA 2003; 289:1414-1420.
9. Deber RB. Shared decision making in the real world. J Gen Intern Med 1996; 11:377-378.
10. Leard LE, Savides TJ, Ganiats TG. Patient preferences for colorectal cancer screening. J Fam Pract 1997; 45:211-218.
11. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-532.
12. Fearon ER, Vogelstein B. A genetic model for tumorigenesis. Cell 1990; 61:759-767.
13. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36:2251-2270.
14. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 368:558-561.
15. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-819.
16. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-816.
17. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75:1215-1225.
18. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359:403-404.
19. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93:858-865.
20. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119:1219-1227.
21. de la Chapelle A. Testing tumors for microsatellite instability. Eur J Hum Genet 1999; 7:407-408.
22. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355:1745-1750.
23. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027-1038.
24. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Nat Acad Sci USA 2000; 97:710-715.
25. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256:102-105.
26. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002; 315:157-168.
27. Syngal S, Chung D, Willett C, et al. Stool DNA analysis for the detection and follow-up of colorectal cancer (CRC) and advanced adenomas (AA): sensitivity in a prospective series. Am J Gastroenterol 2002; 97(suppl):S109.
28. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346:311-320.
29. Brand RE, Shuber AP, Laken SJ, et al. Stool-based DNA mutation testing for colorectal cancer detection: sensitivity and reproducibility. Poster # 117 presented at the 66th Annual Scientific Meeting of the American College of Gastroenterology; October 19-24, 2001; Las Vegas, NV.
30. Tagore K, Ross M, Shuber A, et al. Stool-based DNA multi-target assay for the detection of colorectal cancer (CRC) and advanced adenomas [abstract]. Gastroenterology 2002; 122:A481.
31. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliated stool screening markers. Hum Pathol 2000; 31:51-57.
32. Schroy PC, Heeren, TC. A comparative study of patient perceptions and screening preferences for stool-based DNA testing (SBDNA), fecal occult blood testing (FOBT), or colonoscopy (CS) [abstract]. Gastroenterology 2003; 124:A481.
33. Vanness DJ, Ahlquist DA. Discrete event simulation of the cost-effectiveness of colorectal cancer screening by a DNA-based stool test relative to current screening practice [abstract]. Gastroenterology 2001; 120:A406.
34. Ness R, Klein R, Dittus R. The cost-effectiveness of fecal DNA testing for colorectal cancer [abstract]. Gastrointest Endosc 2003; 57(5):622.
35. Song K, Ladabaum U. Potential cost-effectiveness of molecular stool marker testing compared to conventional colorectal cancer (CRC) screening methods [abstract]. Gastroenterology 2003; 124:A603.